Porton Pharma Solutions Future Growth
Future criteria checks 5/6
Porton Pharma Solutions is forecast to grow earnings and revenue by 123.9% and 20.6% per annum respectively. EPS is expected to grow by 124.1% per annum. Return on equity is forecast to be 5.3% in 3 years.
Key information
123.9%
Earnings growth rate
124.1%
EPS growth rate
| Pharmaceuticals earnings growth | 18.3% |
| Revenue growth rate | 20.6% |
| Future return on equity | 5.3% |
| Analyst coverage | Low |
| Last updated | 25 Oct 2024 |
Recent future growth updates
Recent updates
Revenues Not Telling The Story For Porton Pharma Solutions Ltd. (SZSE:300363) After Shares Rise 31%
Nov 14
Porton Pharma Solutions Ltd.'s (SZSE:300363) 39% Price Boost Is Out Of Tune With Revenues
Sep 30Porton Pharma Solutions (SZSE:300363) Has Debt But No Earnings; Should You Worry?
Sep 25Is Porton Pharma Solutions (SZSE:300363) Weighed On By Its Debt Load?
Jun 26Analysts Just Shaved Their Porton Pharma Solutions Ltd. (SZSE:300363) Forecasts Dramatically
May 02Does Porton Pharma Solutions (SZSE:300363) Have A Healthy Balance Sheet?
Mar 26Porton Pharma Solutions Ltd.'s (SZSE:300363) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Mar 04Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 4,234 | 349 | N/A | 868 | 2 |
| 12/31/2025 | 3,933 | 207 | N/A | 555 | 4 |
| 12/31/2024 | 3,012 | 15 | N/A | 630 | 3 |
| 9/30/2024 | 2,756 | -391 | -705 | -66 | N/A |
| 6/30/2024 | 2,681 | -314 | -879 | -15 | N/A |
| 3/31/2024 | 2,966 | -122 | -614 | 355 | N/A |
| 12/31/2023 | 3,667 | 267 | -501 | 629 | N/A |
| 9/30/2023 | 4,854 | 880 | -15 | 1,199 | N/A |
| 6/30/2023 | 5,460 | 1,203 | 1,709 | 2,876 | N/A |
| 3/31/2023 | 6,970 | 1,928 | 1,359 | 2,593 | N/A |
| 1/1/2023 | 7,035 | 2,005 | 1,391 | 2,564 | N/A |
| 9/30/2022 | 6,293 | 1,741 | 1,325 | 2,533 | N/A |
| 6/30/2022 | 5,763 | 1,522 | -299 | 850 | N/A |
| 3/31/2022 | 4,005 | 818 | -103 | 779 | N/A |
| 1/1/2022 | 3,105 | 524 | -297 | 480 | N/A |
| 9/30/2021 | 2,614 | 446 | -146 | 415 | N/A |
| 6/30/2021 | 2,402 | 408 | 14 | 487 | N/A |
| 3/31/2021 | 2,224 | 364 | -46 | 439 | N/A |
| 12/31/2020 | 2,072 | 324 | 110 | 504 | N/A |
| 9/30/2020 | 1,958 | 289 | 177 | 524 | N/A |
| 6/30/2020 | 1,852 | 251 | 189 | 400 | N/A |
| 3/31/2020 | 1,689 | 217 | 240 | 441 | N/A |
| 12/31/2019 | 1,551 | 186 | 176 | 351 | N/A |
| 9/30/2019 | 1,430 | 163 | 148 | 290 | N/A |
| 6/30/2019 | 1,299 | 159 | 182 | 337 | N/A |
| 3/31/2019 | 1,225 | 119 | 40 | 174 | N/A |
| 12/31/2018 | 1,185 | 124 | 25 | 194 | N/A |
| 9/30/2018 | 1,191 | 134 | 6 | 163 | N/A |
| 6/30/2018 | 1,101 | 79 | N/A | -20 | N/A |
| 3/31/2018 | 1,039 | 73 | N/A | 170 | N/A |
| 12/31/2017 | 1,184 | 107 | N/A | 291 | N/A |
| 9/30/2017 | 1,242 | 121 | N/A | 276 | N/A |
| 6/30/2017 | 1,307 | 138 | N/A | 458 | N/A |
| 3/31/2017 | 1,399 | 182 | N/A | 398 | N/A |
| 12/31/2016 | 1,327 | 171 | N/A | 285 | N/A |
| 9/30/2016 | 1,194 | 148 | N/A | 183 | N/A |
| 6/30/2016 | 1,097 | 148 | N/A | 74 | N/A |
| 3/31/2016 | 1,029 | 125 | N/A | -14 | N/A |
| 12/31/2015 | 1,021 | 110 | N/A | 112 | N/A |
| 9/30/2015 | 1,155 | 142 | N/A | 349 | N/A |
| 6/30/2015 | 1,156 | 138 | N/A | 316 | N/A |
| 3/31/2015 | 1,072 | 127 | N/A | 304 | N/A |
| 12/31/2014 | 987 | 125 | N/A | 122 | N/A |
| 9/30/2014 | 719 | 71 | N/A | -90 | N/A |
| 6/30/2014 | 739 | 88 | N/A | -9 | N/A |
| 3/31/2014 | 723 | 90 | N/A | 42 | N/A |
| 12/31/2013 | 734 | 100 | N/A | 114 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 300363 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.8%).
Earnings vs Market: 300363 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 300363 is expected to become profitable in the next 3 years.
Revenue vs Market: 300363's revenue (20.6% per year) is forecast to grow faster than the CN market (13.8% per year).
High Growth Revenue: 300363's revenue (20.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 300363's Return on Equity is forecast to be low in 3 years time (5.3%).